Vertex Pharmaceuticals price target raised to $590 from $485 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $590 from $485 and keeps an Overweight rating on the shares. Vertex reassured investors on Q4 by maintaining strong expectations for RAINIER, highlighting RUBY-3 80mg data as a relevant benchmark, downplaying hypogammaglobulinemia or infection concerns, positioning the renal franchise as comparable in scale to its more than $12B cystic fibrosis business, and providing 2026 top-line guidance slightly above consensus, the analyst says in a research note.